» Articles » PMID: 28991884

HIV Continuum of Care for Youth in the United States

Abstract

Background: Beneficial HIV treatment outcomes require success at multiple steps along the HIV Continuum of Care. Youth living with HIV are a key population, and sites in the Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) are known for modeling optimum HIV adolescent care.

Methods: A longitudinal cohort study conducted at 14 network sites across the United States assessed how the later steps of the Continuum of Care were achieved among the youth: engagement, treatment, and viral load (VL) suppression. Youth aged 13-24 who were behaviorally infected with HIV and linked to care at an ATN-affiliated site were eligible to participate.

Results: A total of 467 youth were enrolled and had 1 year of available data. Most were aged 22-24 (57%), male (79%), and black/non-Hispanic (71%). Most used alcohol (81%) and marijuana (61%) in the 3 months before enrollment, and 40% had a history of incarceration. Among this cohort of youth, 86% met criteria for care engagement; among these, 98% were prescribed antiretroviral therapy and 89% achieved VL suppression. Sustained VL suppression at all measured time points was found among 59% with initial suppression. Site characteristics were notable for the prevalence of adherence counseling (100%), case management (100%), clinic-based mental health (93%), and substance use (64%) treatment.

Conclusions: Youth living with HIV in the United States can be successfully treated at health care sites with experience, excellence, and important resources and services. Sustained VL suppression may be an important step to add to the Continuum of Care for youth.

Citing Articles

Engaging Diverse African American/Black and Latine Youth and Emerging Adults Living with HIV into Research: Description of Recruitment Strategies and Lessons Learned.

Serrano S, Wilton L, Sherpa D, Cleland C, Zaldivar M, Maria Z AIDS Behav. 2024; 29(1):356-376.

PMID: 39395069 DOI: 10.1007/s10461-024-04524-7.


Overview of the Epidemiology and Clinical Care Considerations for Adolescents and Young Adults Living with or at Risk of Human Immunodeficiency Virus.

Leonard A, Duroseau B Nurs Clin North Am. 2024; 59(2):329-344.

PMID: 38670698 PMC: 11058420. DOI: 10.1016/j.cnur.2024.03.002.


Determinants of an HIV Preventive Vaccine among a Highly Vulnerable Population: African American Men Who Have Sex with Men.

Xu M, Choi J, Rosenberger J, Zimmerman R, DiClemente R Vaccines (Basel). 2024; 12(3).

PMID: 38543957 PMC: 10974539. DOI: 10.3390/vaccines12030323.


Viral load and sexually transmitted infection testing among youth with HIV in a southern United States clinic.

Budhwani H, Hao J, Maragh-Bass A, Hill S, Long D, Simpson T Int J STD AIDS. 2023; 35(1):11-17.

PMID: 37678958 PMC: 11435947. DOI: 10.1177/09564624231200917.


Durable Viral Suppression Among Young Adults Living with HIV Receiving Ryan White Services in New York City.

Feldman M, Montero N, Thomas J, Hoffman S, Nguyen N, Lentz C AIDS Behav. 2023; 27(10):3197-3205.

PMID: 37084103 DOI: 10.1007/s10461-023-04040-0.


References
1.
Agwu A, Fleishman J, Korthuis P, Siberry G, Ellen J, Gaur A . Disparities in antiretroviral treatment: a comparison of behaviorally HIV-infected youth and adults in the HIV Research Network. J Acquir Immune Defic Syndr. 2011; 58(1):100-7. PMC: 3159724. DOI: 10.1097/QAI.0b013e31822327df. View

2.
Kahana S, Jenkins R, Bruce D, Fernandez M, Hightow-Weidman L, Bauermeister J . Structural Determinants of Antiretroviral Therapy Use, HIV Care Attendance, and Viral Suppression among Adolescents and Young Adults Living with HIV. PLoS One. 2016; 11(4):e0151106. PMC: 4817971. DOI: 10.1371/journal.pone.0151106. View

3.
Kahana S, Fernandez M, Wilson P, Bauermeister J, Lee S, Wilson C . Rates and correlates of antiretroviral therapy use and virologic suppression among perinatally and behaviorally HIV-infected youth linked to care in the United States. J Acquir Immune Defic Syndr. 2015; 68(2):169-77. PMC: 4312477. DOI: 10.1097/QAI.0000000000000408. View

4.
Saberi P, Mayer K, Vittinghoff E, Naar-King S . Correlation between use of antiretroviral adherence devices by HIV-infected youth and plasma HIV RNA and self-reported adherence. AIDS Behav. 2014; 19(1):93-103. PMC: 4250439. DOI: 10.1007/s10461-014-0806-z. View

5.
Kim S, Gerver S, Fidler S, Ward H . Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta-analysis. AIDS. 2014; 28(13):1945-56. PMC: 4162330. DOI: 10.1097/QAD.0000000000000316. View